Identification of alternative pathways of caspase activation is an important step to develop new antitumor treatments. We report here the result of a screening with a small chemical library, the Developmental Therapeutics Program-National Cancer Institute ''challenge set,'' on cells expressing mutated caspase-9. We have identified two molecules capable of activating an apoptosome-independent apoptotic pathway. These compounds, named F6 and G5, target the ubiquitinproteasome system by inhibiting the ubiquitin isopeptidases. We have shown that F6 and G5 induce a rather unique apoptotic pathway, which includes a Bcl-2-dependent but apoptosome-independent mitochondrial pathway with upregulation of the BH3-only protein Noxa, stabilization of the inhibitor of apoptosis antagonist Smac, but also the involvement of the death receptor pathway. Noxa plays an important role in the induction of mitochondrial fragmentation and caspase activation, whereas the death receptor pathway becomes critical in the absence of a functional apoptosome. This study suggests that screening of chemical libraries on cancer cells with defined mutations in apoptotic key elements can lead to the identification of compounds that are useful to characterize alternative pathways of caspase activation. (Cancer Res 2006; 66(18): 9235-44) 
Introduction
Apoptosis is the most common mechanism through which many chemotherapeutic drugs kill neoplastic cells and promote tumor eradication (1) . Although it is now emerging that cells can also die by nonapoptotic mechanisms, apoptosis is regarded the preferred mechanism for chemotherapeutic drugs to kill tumor cells. In fact, apoptosis resistance plays a critical role in the efficiency of chemotherapy, with chemoresistance and tumor progression often arising when cancer cells accumulate mutations in the critical genes regulating the apoptotic program (1, 2) .
Apoptosis relies on the timing activation of caspases, a group of cysteine proteases that cleave selected cellular substrates after aspartic residues (3) . Two main apoptotic pathways keep in check caspase activation. The extrinsic pathway is triggered by the activation of a family of death receptors at the cell surface and controls the activation of caspase-8, whereas the intrinsic pathway is triggered by the release of killer proteins, such as cytochrome c and Smac/DIABLO (4) (5) (6) , and induces the assembly of the apoptosome and the activation of caspase-9.
The mitochondrial or intrinsic apoptotic pathway governs cell death in response to various cellular stresses, including many of the available antitumor treatments. Genetic mutations in critical elements of the mitochondrial pathway are often observed in tumors and correlate with chemoresistance (7). To identify new compounds able to induce caspase activation and cell death by alternative mechanisms, we have used cells expressing a dominant-negative form of caspase-9 (C9DN), which interferes with the formation of a functional apoptosome (8) . Fifty-seven compounds that constitute the challenge set of the Developmental Therapeutics Program (DTP) from the National Cancer Institute (NCI) United States (US), with unknown mechanism of cell killing, were evaluated for their ability to trigger caspase activation and apoptosis in apoptosome-defective cells. We have identified two compounds, named F6 and G5, which efficiently activate caspases and apoptosis in the absence of a functional apoptosome. These molecules target the ubiquitin-proteasome system by inhibiting the ubiquitin isopeptidase activities. In this work, we have characterized the apoptotic pathway activated by F6 and G5.
Materials and Methods
Culture conditions, apoptosis, and transfection. IMR90-E1A (E1A) and E1A/C9DN cells have been described previously (8) . All the cell lines, with the exception of the BJ, were grown in DMEM supplemented with 10% FCS. BJ human foreskin fibroblasts expressing the different oncogenes (9, 10) were maintained in MEM with Earle's salts supplemented with nonessential amino acids and 10% fetal bovine serum at 37jC in 5% CO 2 . In all trypan blue exclusion assays, 160 to 400 cells from three independent samples were counted for each data point. Data were represented as arithmetic mean F SD for at least three independent experiments. Stealth RNA interference (RNAi) were purchased from Invitrogen (Carlsbad, CA): Noxa RNAi, GCTGGAAGTCGAGTGTGCTACTCAA (bp 233-257); Apaf-1 RNAi, GGGTACAGTACTTTCTTGTGACATT (bp 3255-3279); histone deacetylase 4 (HDAC4) RNAi, CCACCGGAATCTGAACCACTGCATT (bp 561-585); and the control RNAi, TGCGTTAGTAACGATTTCATTGGAA. Cells were transfected 24 hours after plating by adding the Opti-MEM medium containing LipofectAMINE (Invitrogen) plus the stealth RNAi oligos.
Different drug concentrations were used to determine the dose-response profile and to calculate the IC 50 value, the concentration used to obtain 50% of cell death, after 24 hours of treatment. For drug screening, cells were seeded in 96-wells plates at a density of 5 Â 10 4 /mL per well in 0.1 mL of medium. After 24 hours, cells were incubated with the required concentrations of the 57 compounds that constitute the challenge set obtained from the DTP-NCI-US. 1 After 24 or 48 hours of incubation, cell death was evaluated by trypan blue staining.
Subcellular fractionation. Cells were plated (5 Â 10 compounds. After 20 hours, apoptotic and adherent cells were collected in the lysis buffer (1 mmol/L MgCl 2 , 1 mmol/L EDTA, 1 mmol/L EGTA, 20 mmol/L HEPES, 250 mm/L sucrose, 75 Ag/mL digitonin) in the presence of a cocktail of protease inhibitors. Lysates were centrifuged at 13,000 rpm to separate the pellet containing mitochondria from the cytosolic fraction. Western blotting. Proteins obtained after a SDS denaturating lysis and sonication were transferred to a 0.2-Am pore size nitrocellulose membrane and incubated with the following antibodies: anti-caspase-2, anti-Smac/DIABLO (9), anti-green fluorescent protein (GFP; ref. 11), anti-poly(ADP-ribose) polymerase (PARP; Cell Signaling, Beverly, MA), anti-p85 PARP fragment (Promega, Madison, WI), anti-tubulin, anti-cytochrome c (Cell Signaling), anti-HDAC4 (11), anti-Apaf-1, anti-hemagglutinin (HA; Sigma, St. Louis, MO), anti-F1-ATP synthase, anti-Mcl-1 (Cell Signaling), anti-Bim (Cell Signaling), anti-Noxa (Calbiochem, San Diego, CA), and anti-Bcl-2 (Sigma).
In vitro proteolytic assays. For proteasome and ubiquitin isopeptidase activity assays, two fluorescent substrates were used: Suc-LLVY-AMC and z-LRGG-AMC, respectively (Bachem, Bubendorf, Switzerland). Cells were lysed in 25 mmol/L HEPES (pH 7.5), 5 mmol/L EDTA, and 0.1% CHAPS for 30 minutes at 4jC. The protein concentration was adjusted to 1 mg/mL. For the isopeptidase activity assay, cell lysates were preincubated for 30 minutes at 4jC with 10 Amol/L MG-132 to minimize the background proteolytic activity of the proteasome (12) . Next, the different compounds were added for 30 minutes at 4jC. Finally, the assay mixture was incubated with the substrates at 37jC and the AMC fluorescence was quantified by exciting the samples at k = 360 nm and monitoring the emission at k = 460 nm. Fluorogenic caspase-3/caspase-7 peptide substrate assays (Promega) were done as described previously (9) .
Immunofluorescence microscopy. Mitochondria were labeled in vivo for 1 hour with 25 nmol/L MitoTracker Red CMXRos (Molecular Probes, Eugene, OR). After 12 hours of treatment with the different compounds, cells were fixed with 3% paraformaldehyde in PBS for 20 minutes at room temperature. Fixed cells were washed with PBS/ 0.1 mol/L glycine (pH 7.5) and then permeabilized with 0.1% Triton X-100 in PBS for 5 minutes. The coverslips were treated with the anti-Smac antibodies diluted in PBS for 30 minutes in a moist chamber at 37jC. They were then washed twice with PBS and incubated with Alexa Fluor 488-conjugated secondary antibodies (Molecular Probes) for 30 minutes at 37jC. Cells were examined by epifluorescence with a Zeiss (Oberkochen, Germany) Axiovert 35 microscope or with a Leica (Wetzlar, Germany) SP laser scan microscope equipped with a 488-nm argon laser and a 543-nm helium neon laser.
Results
Identification of two compounds capable of triggering caspase activation in the presence of mutated caspase-9. To identify new compounds capable of triggering caspase activation and apoptosis with high efficiency even in the presence of a nonfunctional apoptosome, the challenge set (DTP-NCI), consisting of 57 molecules with unknown mechanisms of cell killing, was tested for the ability to induce apoptosis in E1A cells. All the different compounds were initially tested to define their IC 50 (50% of apoptosis) in E1A cells. The range of concentration used varied from 0.01 to 40 Amol/L depending on the compound; the appearance of apoptosis was scored up to 48 hours from treatment. Once the IC 50 was defined for each compound, we tested the caspase activity in E1A and in E1A/C9DN cells, which express C9DN (8) . The activity of caspase-3/caspase-7 was measured with the z-DEVD-R110 fluorogenic substrate. After this screening (Fig. 1A) , two compounds were identified: 4H-thiopyran-4-one, tetrahydro-3,5-bis[(4-nitrophenyl)methylene]-,1,1-dioxide (NSC 144303) and 4-piperidione,3,5-bis[(4-methylphenyl)methylene]-hydrochloride (NSC 632839), both capable of sustaining caspase-3/caspase-7 activity in the absence of a functional caspase-9. For simplicity, NSC 144303 and NSC 632839 have been nominated G5 and F6, respectively. As summarized in Fig. 1B, F6 and G5 were able to activate caspase-3/ caspase-7 with similar intensity in E1A and E1A/C9DN cells; we used the proteasome inhibitor MG-132 as a caspase-9-independent positive control (9) and etoposide as a caspase-9-independent negative control (8) . In accordance with the data from the fluorogenic assays, immunoblots showed similar amounts of processed caspase-2 and PARP in E1A and E1A/C9DN cells after treatment with F6, G5, or MG-132. For etoposide, both caspase-2 and PARP processing were drastically reduced in E1A/C9DN cells (Fig. 1C) . Similarly to MG-132, F6 and G5 induced cell death at comparable levels in both cell lines, whereas etoposide, as expected, triggered apoptosis less efficiently in E1A/C9DN cells (Fig. 1D) . Finally, the induction of apoptosis was confirmed by Annexin V/propidium iodide staining and flow cytofluorimetric detection ( Supplementary Fig. S1 ).
The IC 50 (the concentration required to obtain 50% of cell death) for F6 was 15.65 and 16.23 Amol/L in E1A and E1A/C9DN cells, respectively, whereas G5 is a more potent apoptotic inducer showing a IC 50 of 1.76 and 1.6 Amol/L in E1A and E1A/C9DN cells, respectively ( Supplementary Fig. S2 ). We also confirmed that F6 and G5 induce apoptosis with undistinguishable kinetics in E1A and E1A/C9DN cells ( Supplementary Fig. S3 ).
F6 and G5 can induce caspase activation and apoptosis independently from Apaf-1. We down-regulated Apaf-1 expression in E1A cells to further confirm the ability of F6 and G5 to overcome the apoptosome. Stealth RNAi oligos for Apaf-1 and HDAC4, selected as a control ( Fig. 2A) , were transfected in E1A cells. The apoptotic response to F6, G5, MG-132, and etoposide was measured by trypan blue staining. As expected, down-regulation of Apaf-1 significantly reduced the apoptotic response of E1A cells to etoposide but not to F6, G5, or MG-132 (Fig. 2B ). Fluorogenic peptide cleavage assays confirmed that silencing Apaf-1 does not significantly affect the activity of caspase-3/caspase-7 when cells were challenged with F6, G5, or MG-132. By contrast, the presence of the Apaf-1 RNAi oligos clearly impaired the ability of etoposide to trigger caspase activation (Fig. 2C) . The proteolytic processing of caspase-2 and PARP ( Fig. 2D ) was used to confirm that F6 and G5, but not etoposide, induced efficient caspase activation and apoptosis in Apaf-1-depleted cells. These data confirm that F6 and G5 can efficiently trigger caspases activation and apoptosis in the absence of a functional apoptosome.
Bcl-2 family members control F6-and G5-induced apoptosis. Transformed cells display a greater susceptibility to drug-induced apoptosis than nonmalignant cells (1) . Accordingly, we have observed that primary human fibroblasts are more resistant to apoptosis induced by F6 or G5 compared with the counterpart of E1A-transformed cells ( Fig. 3A ; Supplementary  Fig. S1 ).
We next investigated the role of Bcl-2 in the apoptotic pathway elicited by F6 and G5. We used BJ cells transformed with E1A, Ras, and expressing Bcl-2. As shown in Fig. 3B and Supplementary  Fig. S4 , cells overexpressing Bcl-2 were protected by F6-and G5-induced cell death. Bcl-2 protection was also evident in a longterm survival assay ( Supplementary Fig. S5 ). This indicates that Bcl-2 protects cells from F6-and G5-dependent apoptosis and that these cells are not damaged and can resume proliferation.
Multidomain proapoptotic proteins Bax and Bak are required for the apoptotic response to many insults (13) . To unveil the role of these proteins during F6-and G5-dependent apoptosis, immortalized wild-type (WT) murine embryonic fibroblasts (MEF) and bax À/À bak À/À MEFs were treated with F6 and G5. Both F6 and G5 require Bax and Bak to induce cell death ( Fig. 3C ; Supplementary Fig. S6 ). Of note, a concentration up to 40 Amol/L of F6 was necessary to efficiently kill transformed MEFs.
The role of the extrinsic pathway in the apoptotic response to F6 and G5. To investigate the role of the extrinsic pathway in the apoptotic response to F6 and G5, we used competitors of caspase-8 activation, such as c-FLIP S or the dominant-negative form of FADD and CrmA, the natural inhibitor of caspase-8 catalytic activity. The different cDNAs were transfected in E1A and E1A/C9DN cells together with enhanced GFP (EGFP) as a reporter; after treatment with the indicated stressors, apoptosis was measured by scoring the appearance of membrane blebbing and cell collapse in the EGFP-positive cells.
Expression of CrmA, c-FLIP S , and FADD/DN does not influence cell death in response to F6, G5, MG-132, or etoposide in E1A cells, whereas, as expected, apoptosis in response to tumor necrosis factor-a (TNF-a) was impaired (Fig. 4) . This result shows that the death receptor pathway is not critical for the apoptotic response to F6 and G5 in the presence of a functional apoptosome. By contrast, expression of CrmA, c-FLIP S , or FADD/DN in E1A/C9DN cells partially hampered the apoptotic response to F6, G5, and MG-132. These results reveal that the death receptor pathway can compensate for the absence of a functional apoptosome when apoptosis is induced by F6, G5, or MG-132 but not by etoposide.
F6 and G5 interfere with the ubiquitin-proteasome system. Careful inspection for the presence of structural motifs that could predict the cellular targets of F6 and G5 allowed us to identify a recent characterized molecular determinant that confers the ability to inhibit the ubiquitin-proteasome system. F6 and G5 are typified by a cross-conjugated a,h-unsaturated dienone with two sterically accessible electrophilic h-carbons, a determinant that confers isopeptidase inhibitory activity ( Fig. 5A; refs. 12, 14-16 ).
To confirm that F6 and G5 can inhibit the ubiquitin-proteasome system, we tested whether an accumulation of polyubiquitins could be observed in cells after treatment with these compounds. E1A cells transfected with HA-tagged ubiquitin were treated with F6, G5, DBA, a previously characterized isopeptidase inhibitor, DPTP, a compound with sterically hindered h-carbons that does not inhibit isopeptidase activity (12), MG-132, and etoposide. EGFP was coexpressed as a transfection control efficiency. Figure 5B shows that only F6, G5, and DBA, similarly to the proteasome inhibitor MG-132, provoke the accumulation of polyubiquitins, whereas the other compounds do not.
To confirm the ability of F6 and G5 to target the isopeptidases, we first excluded that F6 and G5 could inhibit the catalytic activity of the proteasome. We examined hydrolysis of a substrate for the chymotrypsin-like (Suc-LLVY-AMC) sites of the 20S catalytic subunit of the proteasome, which play a pivotal role in protein cleavage (17, 18) . Addition of F6 or G5 to cell extracts obtained from E1A cells did not inhibit the proteolytic activity of the proteasome, whereas MG-132, as expected, potently inhibited the cleavage of the LLVY-AMC substrate (Fig. 5C) . Next, we measured inhibition of isopeptidase activity by using a previously described assay (14) , which relies on the fluorogenic peptide z-LRGG-AMC that mimics the ubiquitin COOH-terminal isopeptide linkage. In this case, a concentration-dependent inhibition of the isopeptidase substrate cleavage was observed when cell extracts were incubated with F6, G5, or DBA (Fig. 5D ). As expected, the sterically hindered compound DPTP was ineffective as an isopeptidase inhibitor (12) . F6 and G5 increase the level of cytosolic Smac/DIABLO and of the Bcl-2 proteins regulated by the ubiquitin-proteasome system. The expression of various elements of the apoptotic machinery is under the tight control of the ubiquitin-proteasome system (19) . Among them, various data indicate that the inhibitor of apoptosis (IAP) antagonist Smac/DIABLO could be targeted for degradation by the action of the RING finger IAPs after release in the cytosol (20) . Hence, we analyzed the levels of cytosolic Smac when apoptosis was induced by F6 and G5 in comparison with etoposide. Subcellular fractionations were done to isolate the mitochondrial and the cytosolic fractions from E1A cells treated with F6, G5, MG-132, or etoposide. We used doses of the different compounds that had previously been tested to trigger comparable apoptosis. Trypan blue scoring, HDAC4, and PARP processing as detected by immunoblot confirmed that apoptosis was similarly induced by the different insults (Fig. 6A) .
Surprisingly, we noted a second form of Smac/DIABLO with reduced mobility in SDS-PAGE in the pellet fraction obtained from cells treated with the inhibitors of the ubiquitin-proteasome system (Fig. 6A, asterisk) . This form displays the predicted size of the pro-Smac, which includes the NH 2 -terminal presequence for mitochondrial targeting. It is interesting to note that the ability of proteasome inhibitors to alter the import of mitochondrial preproteins has already been documented (21) . Further studies are required to clarify if this additional form of Smac represents its precursor. Most importantly, the levels of Smac in the cytosolic fractions were higher when apoptosis was elicited by F6, G5, or MG-132 compared with etoposide. The levels of cytochrome c and the rate of HDAC4 processing were similar under the different apoptotic insults. This suggests that differences in the amounts of cytosolic Smac cannot be attributed to differences in the permeability of the mitochondrial outer membrane.
The expression of some Bcl-2 family members is modulated by the proteasome (19) . To further confirm the action of F6 and G5 on the ubiquitin-proteasome system, we investigated whether these compounds could modulate the levels of the Bcl-2 family members proven to be under the proteasome control. We focused our attention on Mcl-1, Noxa, Bcl-2, and Bim. F6 and G5 dramatically increased the levels of Noxa and Mcl-1 in E1A cells during a time course analysis. As expected, also MG-132 induced higher levels of Mcl-1 and Noxa, whereas etoposide did not. In our cell line, Bim was not up-regulated in response to alterations of the ubiquitinproteasome system (Fig. 6B) . This probably reflects its tissuespecific modulation by the proteasome (22) . Accordingly to recent data, Bcl-2 was not modulated by proteasome inhibitors during the time of the analysis (23, 24) .
To determine the role of Noxa during F6-and G5-induced apoptosis, its expression was down-regulated by RNAi in E1A/ C9DN cells. As shown in Fig. 6C , Noxa induction by F6 and G5 was efficiently inhibited by the specific stealth RNAi oligos but not by the control oligos. Down-regulation of Noxa has a minimal effect on the accumulation of the putative Smac precursor (Fig. 6C) . When apoptosis was scored by trypan blue exclusion and caspase activity, it was evident that down-regulation of Noxa inhibited but did not completely suppress apoptosis and caspase activation in response to F6, G5, or MG-132 (Fig. 6D-E) . These results indicate that Noxa plays an important role in the apoptotic pathway activated by F6 and G5 and that alternative mechanisms are operating in the absence of Noxa.
Mitochondrial fragmentation is an early response to proteasome alterations and depends on induction of Noxa. A delicate balance of fission and fusion normally controls the morphology of mitochondria. During apoptosis, mitochondria undergo morphologic changes resulting in the generation of small round organelles (25) . This process has been described as mitochondrial fragmentation. We noted that in F6-and G5-treated cells, mitochondria presented altered morphologies; hence, we decided to explore in detail the effect of these compounds on mitochondrial morphology. Because there is a temporal relationship between mitochondrial fragmentation and the release of cytochrome c (26), we scored mitochondrial fragmentation in relation to mitochondrial outer membrane permeabilization (MOMP). The release of Smac into the cytosol was used as an indicator of MOMP. Double immunofluorescence experiments were done to visualize mitochondrial morphology (MitoTracker labeling) and Smac subcellular localization. As illustrated in Fig. 7A , three phenotypes can be distinguished in cells treated with apoptotic stressors in terms of mitochondrial fragmentation and MOMP: cells that present an extended mitochondrial tubular network, cells with fragmented mitochondria but with intact outer mitochondrial membrane, and, finally, cells with fragmented mitochondria and MOMP.
The different apoptotic inducers were characterized by their ability to induce mitochondrial fragmentation (Fig. 7B) . F6, G5, and MG-132 provoke mitochondrial fragmentation in a higher percentage of cells with an intact outer mitochondrial membrane compared with etoposide. This suggests that proteasome inhibitors can alter mitochondrial morphology before MOMP. Caspase-9 mutation does not affect mitochondrial fragmentation but instead augmented the percentage of cells showing MOMP as a consequence of the delayed cellular dismantling.
Under certain conditions, BH3-only proteins can regulate mitochondrial fission (27) . Hence, we decided to investigate whether Noxa stabilization plays any role in the early mitochondrial fission induced by F6 and G5.
Noxa induction was suppressed by the specific small interfering RNA, and cells were analyzed for mitochondrial fragmentation and MOMP as described above. Figure 7C illustrates that Noxa induction plays an important role in mitochondrial fragmentation in response to alterations of the ubiquitin-proteasome system. Nevertheless, because Noxa silencing reduces but does not completely suppress mitochondrial fragmentation, alternative mechanisms may exist that synergize with Noxa.
Discussion
In this report, we have characterized the apoptotic pathway activated by two compounds, 4-piperidione,3,5-bis[(4-methylphenyl)methylene]-hydrochloride and 4H-thiopyran-4-one, tetrahydro-3,5-bis[(4-nitrophenyl)methylene]-,1,1-dioxide, which belong to the challenge set of the DTP-NCI. For simplicity, these compounds have been named F6 and G5 throughout the work.
F6 and G5 have been identified for their ability to initiate a Bcl-2-dependent but apoptosome-independent pathway of caspase activation. This pathway seems to be extremely peculiar given that (a) it was not induced by the other 55 compounds that characterize the challenge set and (b) a large variety of anticancer molecules failed to activate this pathway (9) . A similar Bcl-2-dependent but apoptosome-independent pathway of caspase activation is stimulated by proteasome inhibitors (9) . Hence, it should not be surprising that also F6 and G5 act as inhibitors of the ubiquitin-proteasome system. As a matter of fact, the presence of a pharmacophore that confers inhibitory activity toward ubiquitin isopeptidases (12, (14) (15) (16) and experimental data here reported has confirmed that these new compounds can impede ubiquitin-dependent protein degradation.
Isopeptidases belong to a heterogeneous family of deubiquitinating enzymes (DUB), which can revert the conjugation of ubiquitin to specific substrates and can process inactive ubiquitin. DUBs have been divided into five distinct subfamilies based on structural similarities and mechanisms of action (28, 29) . These subfamilies include a large group of enzymes of which the vast majority are cysteine proteases; only one class includes metalloenzymes. The pharmacophore found in F6 and G5 should inhibit cysteine proteases (30) ; however, which among the different DUBs are the real targets is still unknown. Interestingly, the prostaglandin D12-PGJ2 holds the same pharmacophore of F6 and G5 and similarly induces apoptosis via accumulation of polyubiquitinated proteins (12, 14) ; D12-PGJ2 has been recently suggested to inhibit UCH-L1 and UCH-L3 at micromolar concentrations (15) . It is clear that further studies are required to define in detail which DUBs can be inhibited by F6 and G5.
More in general, our studies suggest that inhibition of the ubiquitin-proteasome system induces apoptosis by a variety of different mechanisms, including up-regulation of the BH3-only protein Noxa, stabilization of the IAP antagonist Smac, and activation of the death receptor pathway. We have noted and confirmed that the levels of Noxa and Smac are modulated by F6, G5, and proteasome inhibitors. The effect on Smac is evident only on the cytosolic fraction where these compounds could counteract the E3 ligase activity of the IAPs. Noxa levels are dramatically induced in response to F6 and G5. The promoter of Noxa is under the control of p53, which can be activated by proteasome inhibitors (31, 32) . Nevertheless, in cancer cells, up-regulation of Noxa transcription in response to bortezomib can take place in p53-dependent and p53-independent manners (23, 24, 33) .
RNAi experiments have shown that Noxa induction is important for apoptosis in response to F6 and G5; however, it should be noted that additional proapoptotic proteins are likely to be involved because only a partial protection was guaranteed by the Noxa RNAi. A possible candidate is NBK/Bik, another BH3-only protein under the proteasome control (34, 35) .
Mitochondrial morphology is maintained by cycles of fission and fusion through the activities of dynamin-like proteins. Optic atrophy 1, mitofusin 1, and mitofusin 2 modulate fusion, whereas Drp1 and FIS1, the ''Drp1 receptor'' on the outer mitochondrial membrane, control fission (25, 26) . Reduced fusion and improved fission can contribute to mitochondrial fragmentation. Studies aimed to deciphering the timing of mitochondrial fragmentation during apoptosis have shown that it coincides with the activation of Bax and Bak as proved by their colocalization in foci on the outer mitochondrial membrane and hence is concurrent with MOMP and cytochrome c release (36, 37) .
A further characteristic feature of the apoptotic response triggered by F6 and G5 is the appearance of mitochondrial fragmentation before MOMP, measured as the release of Smac into the cytosol. Although Noxa induction has a role in this early fragmentation, the effect of its silencing is partial. Again, this should be expected because it is not the solely BH3-only protein capable of regulating mitochondrial fission. Recently, it has been shown that also NBK/Bik can modulate mitochondrial fusion before MOMP through endoplasmic reticulum-mediated Ca 2+ release and Drp1 activation (27, 38) . Therefore, Noxa and NBK/Bik could synergize under the influence of the degradative block induced by F6 and G5.
Although Noxa plays an important role in the apoptotic response to proteasome inhibitors, it is unclear if it can confer apoptosome independence. An unexpected contribution to this independence arises from the role of the death receptor pathway. By expressing CrmA, FADD/DN, and c-FLIP S in E1A/C9DN cells, we have noted that the death receptor pathway can compensate for the absence of a functional apoptosome when apoptosis is induced by inhibitors of the ubiquitin-proteasome system.
How could the inhibitors of the ubiquitin-proteasome system activate the death receptor pathway? Many evidences indicate that elements of the death receptor pathway are under the control of the proteasome. Up-regulation of DR4/TNF-related apoptosisinducing ligand (TRAIL) receptor (TRAIL-R) 1, DR5/TRAIL-R2, and DcR2/TRAIL-R4 on the cell surface of hepatocarcinoma cells was observed after incubation with proteasome inhibitors (39) . Moreover, DR5 is regulated by proteasome inhibitors at multiple levels (40) , including ubiquitination (41) and increased transcription (42) . Proteasome inhibitors can also reduce the levels c-FLIP S and hence synergize with TRAIL to promote apoptosis (43) . It is important to remember that also Smac, which is preserved at higher levels in the cytosol of F6-and G5-treated cells, can synergize with the death receptor pathway (44) (45) (46) (47) (48) (49) . Moreover, artificial expression of cytosolic Smac can bypass the protection afforded by Bcl-2 and potentiate death receptor-induced apoptosis by antagonizing X-linked IAP-mediated inhibition of active caspase-3 and caspase-7 (44, 49) . These authors, similarly to us, hypothesize the existence of a Bcl-2-dependent but Figure 8 . Model for the mechanism of apoptosis induced by F6 and G5. Inhibition of the ubiquitin-proteasome system by F6 and G5 results in the accumulation of Noxa, which contributes to MOMP and Smac release. In the presence of F6 and G5, Smac degradation is impaired and therefore high levels of it accumulate in the cytosol. F6 and G5, in a still undefined manner, could activate the extrinsic pathway, which, with the help of Smac, keeping in check the IAPs, can turn on the effector caspases in the absence of the apoptosome.
apoptosome-independent pathway of caspase activation, which can be activated by the enrollment of the death receptors in concert with cytosolic Smac (49) .
Based on these evidences, we propose the model illustrated in Fig. 8. F6 , G5, and proteasome inhibitors can induce Noxa expression, which plays a part in the release of Smac into the cytosol. The block operated by these compounds on the E3-IAP activities allows the accumulation of higher levels of released cytosolic Smac, which allows in turn to free the effector caspases from the IAP inhibition. Within this scenario, activation of the extrinsic pathway, possibly by modulating the expression and the localization of its various components, can induce activation of caspase-3 and caspase-7 no longer restrained by the IAPs in the absence of the apoptosome.
In conclusion, three considerations can be drawn from these data. First, the inhibition of the ubiquitin-proteasome pathway elicits a rather unique apoptotic response as documented by the apoptosome-independent caspase activation. Second, that not only the proteolytic chamber but also the DUBs are promising targets for new anticancer treatments with a selected mechanism of cytotoxicity (50) . Third, screening of chemical libraries on cancer cells containing defined mutations in elements of the apoptotic program can lead to identification of compounds that are useful to characterize alternative pathways of caspase activation and that can be further developed for clinical applications.
